1 Page 1 2 Page 2 3 Preview 4 Complete
Page 1 of 4 (0%)

Please note that completion of this evaluation form is required to receive credits.

Please complete the evaluation by answering all questions.
*
*
This is required to receive your CEUs/Contact Hours. If you do not have an NABP e-Profile ID or are from outside of the United States, please enter N/A.
*
*
Were these learning objectives achieved?
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Discuss the origin, implication and mandate of the DQSA
Discuss policy that is common to, and discriminates, the Traditional Compounder from the Outsourcing Facility
Explain Federal regulations as presented by OSHA, the CDC and EPA
Distinguish between Category 1 and Category 2 compounded sterile preparations as defined by the USP
Distinguish between non-hazardous and hazardous drug handling
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Summarize the purpose and intent for each of four comprehensive practice management programs
Discriminate, and build relationships, between qualification, quality assurance and quality control
Describe the infrastructure of a standard operating procedure system and its integration into management programs
Explain the purpose and intent of the subsections of well designed standard operating procedures
Apply methods to assess the efficacy, reliability and validity of performance measures
Apply the combined Ishikawa and Failure Mode and Effects Analysis risk strategies to sterile compounding
Apply corrective action and preventive action (CAPA) to identified potential and demonstrated risk
Learn a series of underlying principles applicable to a sterile compounding practice
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Distinguish roles and responsibilities of the designated person, compounding and non-compounding personnel
Review, and apply in practice, qualification, QA and QC competency and compliance indicators
Recall QA and QC procedures for performance testing (i.e., gloved fingertip and thumb sampling and media-fill test)
Summarize requirements leading to a robust media-fill test design for non-hazardous and hazardous drug compounding
Describe a hazardous drug communication program, which includes medical surveillance
Employ strategies to optimize overall personnel performance
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Describe structural, functional and operational EC requirements for non-HD and HD handling and compounding
Determine relative position of EC components (e.g., ceiling filters, plenums, PECs, ceiling vents, doors and pass-throughs)
Determine relative position of EC to equipment to each other, (e.g., sinks, storage units and heat generating equipment)
Describe certification requirements for primary and secondary ECs and containment ECs
Summarize EC operational parameters under dynamic conditions for different cleanroom configurations
Summarize routine assessments and testing of the facility environmental controls
Describe non-viable and viable particulate sampling procedures
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Select vendors based on industry-, and regulatory-, specific qualifications
Select technology based on regulatory-, and standard of practice-, specific requirements
Detail requirements of electromechanical equipment certification, calibration and operational parameters
Describe structural (i.e., made like this), functional (i.e., used for this) and operational (i.e., works like this) technology requirements
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Perform drug conversion calculations (e.g., base to salt form)
Review certificates of analysis, and then adjust drug strength accordingly
Solve for formulation concentration adjustments
Solve for osmolarity and isotonicity
Carry out basic TPN calculations for fluid, protein, carbohydrate and lipid requirements
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Detail workflow procedure for non-hazardous and hazardous sterile compounding facility settings
Recall donning and doffing procedures for non-hazardous and hazardous drug handling
Discuss sanitization workflow procedures for the cleanroom suite
Summarize general rules surrounding aseptic manipulations of a broad range of sterile compounding technology
emonstrate the positioning and order of operation of devices and chemicals in the direct compounding area
Manipulate and explain direct compounding area-specific aseptic techniques
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Reproduce requirements of a well-designed Master Formulation Record template
Assess drug monographs and certificates of analysis
Assess drug strength, pH, isotonicity, chemical sensitivity, chemical compatibility and container-closure requirements
Combine formula ingredients, technique and technology into a preparatory procedure
Select combinatorial methods of filtration and sterilization to reduce preparation pyro-, and bio- burden
Choose beyond-use date time frames, storage, shipping and transportation requirements
Select visual inspection criteria and some procedures (e.g., sterilization method) on the basis formula composition
Describe sterility and bacterial endotoxin test methods
Select inspection procedures integrating, the compounding record, label and compounded sterile preparation
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Discuss the origin, implication and mandate of the DQSA
Discuss policy that is common to, and discriminates, the Traditional Compounder from the Outsourcing Facility
List Federal regulations as presented by OSHA, the CDC and EPA
Define Category 1 and Category 2 compounded sterile preparations as outlined by the USP
Define non-hazardous and hazardous drug handling
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Describe the purpose and intent for each of four comprehensive practice management programs
Identify, and build relationships, between qualification, quality assurance and quality control requirements
Describe the infrastructure of a standard operating procedure system and its integration into management programs
Explain the purpose and intent of the subsections of well designed standard operating procedures
Discuss methods to assess the efficacy, reliability and validity of performance measures
Apply the combined Ishikawa and Failure Mode and Effects Analysis risk strategies to sterile compounding
Apply corrective action and preventive action (CAPA) to identified potential and demonstrated risk
Learn a series of underlying principles applicable to a sterile compounding practice
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Summarize roles and responsibilities of the designated person, compounding and non-compounding personnel
Describe qualification, QA and QC competency and compliance indicators
Recall QA and QC procedures for performance testing (i.e., gloved fingertip and thumb sampling and media-fill test)
Summarize requirements leading to a robust media-fill test design for non-hazardous and hazardous drug compounding
Comply with a hazardous drug communication program, which includes medical surveillance
Comply with strategies to optimize overall personnel performance
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Describe structural, functional and operational EC requirements for non-HD and HD handling and compounding
Explain the relative position of EC components (e.g., ceiling filters, plenums, PECs, ceiling vents, doors and pass-throughs)
Explain the relative position of EC to equipment to each other, (e.g., sinks, storage units and heat generating equipment)
Comply with certification requirements for primary and secondary ECs and containment ECs
Summarize EC operational parameters under dynamic conditions for different cleanroom configurations
Reproduce routine assessments and testing of the facility environmental controls
Comply with non-viable and viable particulate sampling procedures
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Identify vendors based on industry-, and regulatory-, specific qualifications
Identify technology based on regulatory-, and standard of practice-, specific requirements
Recall requirements of electromechanical equipment certification, calibration and operational parameters
Describe structural (i.e., made like this), functional (i.e., used for this) and operational (i.e., works like this) technology requirements
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Perform drug conversion calculations (e.g., base to salt form)
Review certificates of analysis, and then adjust drug strength accordingly
Solve for formulation concentration adjustments
Solve for osmolarity and isotonicity
Perform basic TPN calculations for fluid, protein, carbohydrate and lipid requirements
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Recognize quality workflow procedure for non-hazardous and hazardous sterile compounding facility settings
Recall donning and doffing procedures for non-hazardous and hazardous drug handling
Discuss sanitization workflow procedures for the cleanroom suite
Summarize general rules surrounding aseptic manipulations of a broad range of sterile compounding technology
Demonstrate the positioning and order of operation of devices and chemicals in the direct compounding area
Manipulate and explain direct compounding area-specific aseptic techniques
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Describe requirements of a well-designed Master Formulation Record template
Assess drug monographs and certificates of analysis
Comply with drug strength, pH, isotonicity, chemical sensitivity, chemical compatibility and container-closure requirements
Use formula ingredients, technique and technology as indicated in a preparatory procedure
Apply, and comply with combinatorial methods of filtration and sterilization to reduce preparation pyro-, and bio- burden
Explain beyond-use date time frames, storage, shipping and transportation requirements
Recognize visual inspection criteria and some procedures (e.g., sterilization method) on the basis formula composition
Relate sterility and bacterial endotoxin test methods to preparation quality
Describe inspection procedures integrating, the compounding record, label and compounded sterile preparation